PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

NCT05543707 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

242

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis concluded primary endpoint was not met

Conditions

COVID-19

Interventions

DRUG: PBI-0451 (Pomotrelvir)
DRUG: Placebo

Sponsor

Pardes Biosciences, Inc.